TsGRM Genetiko PAO

TsGRM Genetiko PAO FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of TsGRM Genetiko PAO (GECO.ME) as of Oct 22, 2026 is 251.89 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 232.65 % — a change of 8.27% (higher).

FCF Conversion

251.89 %

YoY

8.27%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of TsGRM Genetiko PAO is 2024 251.89 % . FCF Conversion Rate (FCF/EBITDA) of TsGRM Genetiko PAO was 2023 232.65 % . It decreases by 8.27% higher compared to the previous year.

The TsGRM Genetiko PAO FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
38.11 RUB
Jan 1, 2023
232.65 RUB
Jan 1, 2024
251.89 RUB
The TsGRM Genetiko PAO FCF Conversion history
YEARFCF ConversionYoY
251.89 %+8.27%
232.65 %+510.44%
38.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TsGRM Genetiko PAO Stock analysis

What does TsGRM Genetiko PAO do? TsGRM Genetiko PAO generates revenue through medical genetic services provided to doctors and patients via its four specialized laboratories. The company offers complex genetic diagnostics for hereditary diseases and reproductive disorders through its Next-Generation Sequencing (NGS) laboratory, Non-Invasive Prenatal Testing (NIPT) laboratory, Oncogenetics laboratory, and Genotyping laboratory. These services are delivered to healthcare professionals and individuals seeking genetic analysis. The firm's laboratory and production complexes form the core of its service delivery model, focusing on diagnostic solutions for medical genetics. TsGRM Genetiko PAO's primary customers are doctors who order genetic tests for their patients and patients directly seeking genetic diagnostics. The company's services include hereditary disease diagnostics and reproductive disorder assessments, which are conducted in its dedicated laboratory facilities. The firm's business model centers on providing specialized genetic testing services through its internal laboratory infrastructure without external partnerships or additional product lines. The company operates exclusively within the medical genetic services sector, delivering diagnostic solutions through its four laboratory divisions. Revenue is derived from the execution of genetic tests across all laboratory types, with no mention of additional product lines or external collaborations. The firm's structure is defined by its internal laboratory network, which serves both medical professionals and end patients. TsGRM Genetiko PAO is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TsGRM Genetiko PAO stock

FCF Conversion Rate (FCF/EBITDA) of TsGRM Genetiko PAO is 251.89 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of TsGRM Genetiko PAO changed from 232.65 % to 251.89 %, representing a 8.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) TsGRM Genetiko PAO since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s TsGRM Genetiko PAO with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — TsGRM Genetiko PAO

All Key Metrics — TsGRM Genetiko PAO